quinfamide
Small moleculeexperimental
Quinfamide is a drug that has anti-parasitic properties. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Oct 1, 2005 (NCT02385058)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- Entamoeba invadensINHIBITOR
Entamoeba invadens inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(Oc1ccc2c(c1)CCCN2C(=O)C(Cl)Cl)c1ccco1- Mol. weight
- 354.19 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaQuinfamide ↗
- ChEMBLCHEMBL2107014 ↗
Also known as
- 2-furancarboxylic acid, 1-(dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinyl ester
- amenide
- amenide
- amenide
- amenox
- quinfamide
- quinfamide
- quinfamide
- quinfamide
- quinfamide
- quinfamide
- quinfamide
- quinfamide
- win 400 14
- win-40014
- win-40014
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02385058 | Phase 4 | Oct 1, 2005 | Johnson and Johnson |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2005 |
1 organizations
Page 1 / 1